A Polish study of axial spondyloarthritis patients who discontinued treatment with anti–tumor necrosis factor (anti-TNF) therapy because of low disease activity found that more than half eventually needed to restart anti-TNF therapy.
A Polish study of axial spondyloarthritis (axSpA) patients who discontinued treatment with anti—tumor necrosis factor (anti-TNF) therapy because of low disease activity (LDA) found that more than half eventually needed to restart anti-TNF therapy.
Changes in the values of C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR), which were used as disease activity indicators, were correlated with a more stable response to anti-TNF therapy. Patients who resumed anti-TNF treatment had no recurrence of symptoms. The study’s authors, Agata Sebastian, MD, and colleagues, conclude that more study is needed to determine whether and how long anti-TNF treatment should be continued in axSpA patients despite achievement of LDA, and whether the dose of anti-TNF should be reduced to obtain long-term LDA.
The researchers undertook the study, published in the April 2017 issue of Reumatologia, because they said there is presently no formal proof that anti-TNF are in fact disease modifying in axSpA, and it is not clear how long anti-TNF therapy should last and which treatment algorithm to choose when disease activity is low or remission occurs. The authors explain that the Polish National Health Fund program defines active ankylosing spondylitis (AS) as occurring when the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is 4 or greater and LDA as occurring when BASDAI less than 3 persists longer than 6 months. Under the Polish healthcare system rules, anti-TNF therapy can be reinstituted when BASDAI increases to be over 4.
The study followed 65 patients with axSpA who were treated with anti-TNFs (etanercept, 72%; adalimumab, 2%; and infliximab, 3%). The patients were observed from 2009 to 2015 for an average of 9 to 48 months. Prior to anti-TNF treatment, all the patients were treated for 6 months with 2 nonsteroidal anti-inflammatory drugs (NSAIDs), with no clinical effect. Response to therapy was defined as a reduction of 50% or more in BASDAI score, or at least 2 units in visual analogue scale (VAS) for low back pain after 12 weeks of treatment with anti-TNF compared with baseline.
A total of 83% of patients achieved LDA after 9 months of anti-TNF therapy. During follow up, 73% of patients with LDA had an increase in disease activity after a mean of 14 weeks and needed to restart anti-TNF treatment. After treatment was resumed, LDA was regained in all patients after a mean of 7 weeks. Seventeen percent never achieved LDA and 22% had LDA longer than 6 months without relapse. At baseline, higher levels of CRP and ESR were observed in patients with disease relapse at the end of treatment and with LDA shorter than 6 months.
The authors conclude that due to the chronic nature of axSpA, all patients should be given the opportunity to resume anti-TNF treatment because it is the best therapy currently available.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.